ArticleRheumatology advances in practice2026
Sustained improvements in health status and work productivity with bimekizumab in psoriatic arthritis: 2-year results from two phase 3 studies.
Article in Rheumatology advances in practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference (Adalimumab) Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
A Multicenter, Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To assess the 2-year impact of bimekizumab on health status, work productivity and indirect cost savings in patients with active PsA. Methods: BE OPTIMAL [NCT03895203; biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve] and BE COMPLETE [NCT03896581; tumor necrosis factor inhibitor inadequate response/intolerance (TNFi-IR)] assessed subcutaneous bimekizumab 160 mg every 4 weeks. BE OPTIMAL week 52/BE COMPLETE week 16 completers could enter BE VITAL (NCT04009499; open-label extension), where all patients received bimekizumab. Outcomes reported for placebo- and bimekizumab-randomized patients to year 2 were changes in health status (EQ-5D-3L) and work productivity [Work Productivity and Activity Impairment Questionnaire-Specific Health Problem v2.0 (WPAI-SHP)], associations between disease control criteria and WPAI-SHP, and annualized indirect cost savings (estimated by multiplying 2022 average wages by improvements in overall work impairment). Missing data were imputed using multiple (continuous) or non-responder (binary) imputation. Results: Among 712 bDMARD-naïve and 400 TNFi-IR patients, improvements from baseline in mean EQ-5D-3L visual analog scale scores were sustained to year 2, with scores improving by 24.6-38.9%. A minimal clinically important difference in overall work impairment was achieved by 51.1-64.8% of patients at year 1, and this was largely sustained to year 2 (44.3-51.6%). The greatest work productivity improvements were observed in patients who achieved stringent disease control across both musculoskeletal and skin domains. In Europe, indirect cost savings at year 1 (US$7965-11 517) were sustained to year 2 (US$7789-12 018); trends were similar in the USA and Japan. Conclusion: Bimekizumab treatment resulted in sustained improvements in health status and work productivity to year 2, with substantial potential for long-term indirect cost savings, regardless of prior TNFi experience.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.